First Time Loading...

Carna Biosciences Inc
TSE:4572

Watchlist Manager
Carna Biosciences Inc Logo
Carna Biosciences Inc
TSE:4572
Watchlist
Price: 468 JPY 1.08%
Updated: Mar 28, 2024

Intrinsic Value

Carna Biosciences, Inc. engages in the drug discovery business. [ Read More ]

The intrinsic value of one Carna Biosciences Inc stock under the Base Case scenario is 378.31 JPY. Compared to the current market price of 468 JPY, Carna Biosciences Inc is Overvalued by 19%.

Key Points:
Intrinsic Value
Base Case
378.31 JPY
Overvaluation 19%
Intrinsic Value
Price
Worst Case
Base Case
Best Case

Valuation Backtest
Carna Biosciences Inc

Backtest Carna Biosciences Inc Intrinsic Value
Dive into the past to invest in the future

Run backtest to discover the historical profit from buying and selling Carna Biosciences Inc stocks based on their intrinsic value.

Analyze the historical link between intrinsic value and market price to make more informed investment decisions.

Run Backtest
Settings
Valuation Methods
Buy/Sell Thresholds
Buy When:
%
Sell When:
%
B
S
Run Backtest
How does it work?

Fundamental Analysis

How can I assist you today?

Provide an overview
of Carna Biosciences Inc's business.

What risks and challenges
does Carna Biosciences Inc face in the near future?

Summarize the latest earnings report
of Carna Biosciences Inc.

Provide P/E
for Carna Biosciences Inc and its competitors.

Financials

Balance Sheet Decomposition
Carna Biosciences Inc

Current Assets 4.2B
Cash & Short-Term Investments 2.9B
Receivables 788.2m
Other Current Assets 514.2m
Non-Current Assets 158.4m
PP&E 105.5m
Intangibles 1.1m
Other Non-Current Assets 51.8m
Current Liabilities 375.9m
Accounts Payable 1.2m
Other Current Liabilities 374.7m
Non-Current Liabilities 96.4m
Long-Term Debt 56.4m
Other Non-Current Liabilities 40m
Efficiency

Earnings Waterfall
Carna Biosciences Inc

Revenue
1.6B JPY
Cost of Revenue
-175.3m JPY
Gross Profit
1.5B JPY
Operating Expenses
-2.6B JPY
Operating Income
-1.1B JPY
Other Expenses
-35.9m JPY
Net Income
-1.2B JPY

Free Cash Flow Analysis
Carna Biosciences Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate
History
Components
Chart
Table
What is Free Cash Flow?
Fundamental Scores

Profitability Score
Profitability Due Diligence

Carna Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Positive Gross Profit
ROIC is Increasing
Positive 3-Years Revenue Growth
Positive 1-Year Revenue Growth
27/100
Profitability
Score

Carna Biosciences Inc's profitability score is 27/100. The higher the profitability score, the more profitable the company is.

Solvency Score
Solvency Due Diligence

Carna Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

High Altman Z-Score
Short-Term Solvency
Long-Term Solvency
Negative Net Debt
75/100
Solvency
Score

Carna Biosciences Inc's solvency score is 75/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

Price Targets Summary
Carna Biosciences Inc

There are no price targets for Carna Biosciences Inc.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Competitive Landscape

Shareholder Return

Price
Carna Biosciences Inc

1M 1M
+4%
6M 6M
-37%
1Y 1Y
0%
3Y 3Y
-65%
5Y 5Y
-55%
10Y 10Y
-17%
Annual Price Range
468
52w Low
415
52w High
1 024
Price Metrics
Average Annual Return -0.97%
Standard Deviation of Annual Returns 67.57%
Max Drawdown -87%
Shares Statistics
Market Capitalization 8B JPY
Shares Outstanding 17 144 800
Percentage of Shares Shorted
N/A

Return Decomposition
Main factors of price return

What is price return decomposition?

Company Profile

Carna Biosciences Inc Logo
Carna Biosciences Inc

Country

Japan

Industry

Life Sciences Tools & Services

Market Cap

8B JPY

Dividend Yield

0%

Description

Carna Biosciences, Inc. engages in the drug discovery business. The company is headquartered in Kobe, Hyogo-Ken and currently employs 64 full-time employees. The company went IPO on 2008-03-25. The firm operates in two business segments. The Drug Development Support segment is engaged in sales of protein kinase, development of assay, as well as provision of profiling and screening service. The Drug Development segment is engaged in the research and development of kinase inhibitors and other drugs.

Contact

HYOGO-KEN
Kobe
3F, Bma, 1-5-5, Minatojimaminami-machi, Chuo-ku
+81783027039.0
https://www.carnabio.com/

IPO

2008-03-25

Employees

64

Officers

CEO, President & Representative Director
Dr. Kohichiro Yoshino Ph.D.
GM of Business Mgt., Accounting, HR, General Affairs, CFO, Director & President - CarnaBio USA
Ms. Emi Yamamoto
GM of Research & Development Division, Chief Scientific Officer and Director
Dr. Masaaki Sawa Ph.D.
Head of Drug Discovery & Support Business, Head of IP & Legal Department and Director
Mr. Norio Aikawa
GM of Clinical Development, R&D, Chief Development Officer of CarnaBio USA & Director
Dr. Akinori Arimura Ph.D.

See Also

Discover More
What is the Intrinsic Value of one Carna Biosciences Inc stock?

The intrinsic value of one Carna Biosciences Inc stock under the Base Case scenario is 378.31 JPY.

Is Carna Biosciences Inc stock undervalued or overvalued?

Compared to the current market price of 468 JPY, Carna Biosciences Inc is Overvalued by 19%.